• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BioMarin wins FDA approval for injection to increase growth in children with dwarfism

November 19, 2021 By Sean Whooley

BioMarinBioMarin Pharmaceutical (NSDQ:BMRN) announced today that the FDA granted accelerated approval for its Voxzogo injection.

San Rafael, California-based BioMarin’s Voxzogo (vosoritide) injection has an indication to increase linear growth in pediatric patients with achondroplasia (a form of dwarfism) five years of age and older with open epiphysis (growth plates). Continued approval may be contingent upon verification and description of clinical benefit in confirmatory studies, with BioMarin intending to use the ongoing open-label extension studies compared to available natural history.

According to a news release, Voxzogo represents the first FDA-approved treatment for children with achondroplasia. The treatment, a C-type natriuretic peptide (CNP) analog, represents a new class of therapy that acts as a positive regulator of the signaling pathway downstream of FGFR3 to promote endochondral bone growth, the company said.

FDA also issued a Rare Pediatric Disease Priority Review Voucher (PRV) that confers priority review to a subsequent drug application that would otherwise not qualify for such review. BioMarin expects Voxzogo to be available in the U.S. by mid- to late-December, with promotion beginning immediately.

Voxzogo has been approved in Europe since August, while authorization reviews are in progress in Japan, Brazil and Australia. BioMarin has eyes on approvals in those countries in 2022.

“Voxzogo is a medical first that is rooted in BioMarin’s focus on molecular genetics and targets the underlying cause of the condition. More than a decade of scientific research underpins the medical advance that Voxzogo represents. We thank the FDA for recognizing its value as the first therapeutic treatment option for children with achondroplasia,” BioMarin Chair & CEO Jean-Jacques Bienaimé said in the release. “We extend our gratitude to the community, clinical investigators and the children and their families, who participated and continue to participate in our comprehensive clinical research program as we continue to investigate the full potential of vosoritide.”

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pediatrics, Pharmaceuticals, Regulatory/Compliance Tagged With: BioMarin, FDA

IN CASE YOU MISSED IT

  • FDA approves Medtronic’s Onyx Frontier drug-eluting coronary stent
  • Medtronic completes Intersect ENT acquisition
  • Abbott announces availability of Xience Skypoint drug-eluting stent in extended sizes
  • Here’s what’s next for Insulet after the launch of Omnipod 5, CEO change
  • Senseonics beats The Street in Q1 following Eversense E3 launch

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS